Publication details
Zkušenosti s cetuximabem a sledování mutací v signální cestě receptoru pro epidrmální růstový faktor u HNSCC
| Title in English | Our experiences with Cetuximab ande evaluation of mutation in signal pathway EGFR in HNSCC |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Proceedings |
| Conference | 73. kongres České společnosti otorinolaryngologie a chrirugie hlavy a krku |
| MU Faculty or unit | |
| Citation | |
| Keywords | HNSCC;Cetuximab and radiotherapy;mutation of K-ras and EGFRvIII |
| Description | Radiation therapy in combination with cetuximab have been indicated for 18 patients with locoregionally advanced HNSCC in a clinical stage III/IV (oropharynx, hypofarynx or larynx). Complete remission (CR) was achieved after the treatment in 15 patients (83%). Partial remission (PR) or a stable disease (SD) was present in 3 cases; one of them was indicated to salvage surgery, after which he is still staying in complete remission. In the course of genetic analysis, EGFR tyrosine kinase mutation in exon 19 was found in 1 case and K-ras mutations in 3 cases, but without any correlation to the therapeutic response. EGFRvIII was present in 4 cases and most of them did not achieve complete remission after the treatment. |